Specific Cell-derived Microvesicles: Linking Endothelial Function to Carotid Artery Intima-media Thickness in Low Cardiovascular Risk Menopausal Women
Overview
Authors
Affiliations
Background: Decreases in endothelial function measured by reactive hyperemic index (RHI) correlated with increases in carotid intima-media thickness (CIMT) in recently menopausal women with a low risk cardiovascular profile. Factors linking this association are unknown.
Objective: Assess, longitudinally, markers of platelet activation and cell-derived, blood-borne microvesicles (MV) in relationship to RHI and CIMT in asymptomatic, low risk menopausal women.
Methods: RHI by digital pulse tonometry (n = 93), CIMT by ultrasound (n = 113), measures of platelet activation and specific cell-derived, blood-borne MV were evaluated in women throughout the Kronos Early Estrogen Prevention Study (KEEPS) at Mayo Clinic.
Results: CIMT, but not RHI, increased significantly over 4 years. The average change in CIMT correlated significantly with the average follow-up values of MV positive for common leukocyte antigen [CD45; ρ = 0.285 (P = 0.002)] and VCAM-1 [ρ = 0.270 (P = 0.0040)]. Using principal components analysis (PC) on the aggregate set of average follow-up measures, the first derived PC representing numbers of MV positive for markers of vascular endothelium, inflammatory cells (leukocyte and monocytes), pro-coagulant (tissue factor), and cell adhesion molecules (ICAM-1 and VCAM-1) associated with changes in RHI and CIMT. Changes in RHI associated with another PC defined by measures of platelet activation (dense granular ATP secretion, surface expression of P-selectin and fibrinogen receptors).
Conclusions: MV derived from activated endothelial and inflammatory cells, and those expressing cell adhesion and pro-coagulant molecules may reflect early vascular dysfunction in low risk menopausal women. Assays of MV as non-conventional measures to assess cardiovascular risk in asymptomatic women remain to be developed.
Hou Z, Deng L, Fang F, Zhao T, Zhang Y, Li G BMC Biol. 2025; 23(1):20.
PMID: 39838385 PMC: 11753076. DOI: 10.1186/s12915-025-02125-x.
Extracellular Vesicles as Mediators in Atherosclerotic Cardiovascular Disease.
Zisser L, Binder C J Lipid Atheroscler. 2024; 13(3):232-261.
PMID: 39355407 PMC: 11439751. DOI: 10.12997/jla.2024.13.3.232.
Extracellular vesicles as tools and targets in therapy for diseases.
Kumar M, Baba S, Sadida H, Al Marzooqi S, Jerobin J, Altemani F Signal Transduct Target Ther. 2024; 9(1):27.
PMID: 38311623 PMC: 10838959. DOI: 10.1038/s41392-024-01735-1.
Du H, Guo T, Ye H, Bao Y, Qiu Z, Sun Y Front Neurol. 2023; 14:1172488.
PMID: 37475741 PMC: 10354419. DOI: 10.3389/fneur.2023.1172488.
Bioengineering Extracellular Vesicles for the Treatment of Cardiovascular Diseases.
Ramasubramanian L, Du S, Gidda S, Bahatyrevich N, Hao D, Kumar P Adv Biol (Weinh). 2022; 6(10):e2200087.
PMID: 35778828 PMC: 9588622. DOI: 10.1002/adbi.202200087.